Lannett Company LLC, a wholly owned subsidiary of Aurobindo USA, has launched the generic equivalent of GSK’s Advair Diskus (fluticasone propionate and salmeterol inhalation powder) in the US market.
The product has been launched in 100/50 mcg and 250/50 mcg strengths.
The company said the launch marks the first product from its inhalation pipeline to be commercialised in the US, supporting its efforts to expand its portfolio of complex and differentiated inhalation products.
Advair Diskus in combination therapy is indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Aurobindo Pharma USA acquired Lannett for USD 250 million on a cash-free, debt-free basis, inclusive of normalised working capital, in June 2026.
Lannett, a Pennsylvania-based generic pharmaceutical company, specialises in the development and commercialisation of a diversified portfolio of complex, non-opioid controlled substances. The acquisition significantly expands Aurobindo USA’s product portfolio in this segment while adding a US-based manufacturing facility to its network.
Lannett’s manufacturing site in Seymour, Indiana, has the capacity to scale production to approximately 4 billion doses annually, strengthening Aurobindo USA’s domestic manufacturing footprint.
Aurobindo Subsidiary Incorporates Avogent Lifesciences
Separately, Apitoria Pharma, a 100% subsidiary of Aurobindo Pharma, has incorporated a new wholly owned subsidiary, Avogent Lifesciences, in India.
According to Aurobindo Pharma’s stock exchange filing, Avogent Lifesciences will undertake manufacturing and marketing operations in India and international markets.
The subsidiary was incorporated in India on August 31, 2026.
Aurobindo Pharma is an integrated pharmaceutical company headquartered in Hyderabad, India, with operations spanning the development, manufacturing and commercialisation of generic pharmaceuticals, branded speciality medicines and active pharmaceutical ingredients (APIs).
The company operates more than 30 manufacturing and packaging facilities approved by regulatory authorities including the US Food and Drug Administration (USFDA), UK Medicines and Healthcare products Regulatory Agency (MHRA), European Directorate for the Quality of Medicines & HealthCare (EDQM), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), World Health Organization (WHO), Health Canada, South Africa’s Medicines Control Council (MCC) and Brazil’s National Health Surveillance Agency (ANVISA).
Its portfolio covers seven major therapeutic and product areas, including central nervous system (CNS), anti-retroviral, cardiovascular system (CVS), antibiotics, gastroenterology, anti-diabetic and anti-allergic products.
